2026 Set to Transform Weight-Loss Drug Market: India at Forefront of Generic Revolution

• Major GLP-1 weight-loss drugs like Mounjaro, Wegovy, and Ozempic entered India in 2025, with Mounjaro achieving ₹496 crore sales.
• 2026 marks a pivotal year as Semaglutide's patent expires in key markets including India, Canada, and Brazil, opening doors for generics.
• Indian pharma companies are actively partnering and preparing for generic launches, anticipating fierce competition and significant price drops.
• India expects 10-15 generic players post-March 2026 expiry, potentially halving prices to ₹4,000 per month.
• Semaglutide is projected to contribute 4-5% to India's pharma market, adding 1-2% to overall growth, amid a global market boom.

Why It Matters: Semaglutide patent expiry in 2026 will revolutionize India's weight-loss drug market with generics.